TürkiyeResearch and clinical trials
Long-term outcomes of 50 patients with propionic acidemia from Hacettepe
Hacettepe University studied 50 patients diagnosed between 1984 and 2020.
Inborn errors of metabolism
An inherited metabolic disease. The body cannot break down certain proteins and fats, and harmful acids build up. Symptoms usually begin a few days after birth.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
Orphanet has a guideline for emergency doctors for this disease (language: French, English). See on Orphanet
This page is translated from the Turkish original.
This disease is followed through the “Inborn errors of metabolism” group.
An enzyme that breaks down some protein building blocks and fats does not work. Propionic acid and other harmful substances build up. This buildup makes the blood acidic. The brain and nervous system are damaged most.
In most babies, symptoms begin a few days after birth. Less often, it appears in childhood with episodes that come and go.
In many countries, it can be found through expanded newborn screening. Blood and urine tests are done. The diagnosis is confirmed with a genetic test. If a gene change is known in the family, testing before birth is possible.
The basis of care is a low-protein diet planned with a metabolic dietitian, and a special formula. The doctor may recommend some vitamin and nutritional supplements. During an episode, fluids, sugar and, if needed, dialysis are given in hospital. In some people who have frequent episodes, a liver transplant may be considered. New treatments are being researched. The doctor who follows the disease decides which treatment is suitable.
The disease is passed on through recessive inheritance. The mother and father are usually healthy carriers. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. When relatives marry, the chance that two carriers have children together is higher. Genetic counselling guides the family.
Source: MedlinePlus Genetics: Propionic acidemia · NORD: Propionic Acidemia
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
For all rare diseases: Nadir Hastalıklar Federasyonu
Links checked on October 8, 2026.
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
TürkiyeResearch and clinical trials
Hacettepe University studied 50 patients diagnosed between 1984 and 2020.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
Questions you can ask your doctor
ClinicalTrials.gov lists 4 active interventional studies for this disease. 3 are recruiting now; none has a site in Türkiye. Last checked: October 7, 2026.
Selected records (studies with a site in Türkiye first):
Early stage: safety and dose are being tested · Phase 1 · investigational (experimental)RecruitingNCT07643844
Middle stage: the effect is being tested in a small group · Phase 1 / Phase 2 · investigational (experimental)RecruitingNCT05130437
Middle stage: the effect is being tested in a small group · Phase 1 / Phase 2 · investigational (experimental)RecruitingNCT04159103
Non-drug study (device, procedure, care, etc.)Not yet recruitingNCT06664840
See all studies on ClinicalTrials.gov · Joining clinical trials
EUNew treatments and approvals
In Europe, leriglitazone, taken by mouth, was authorized for cerebral adrenoleukodystrophy.
USANew treatments and approvals
Through the accelerated pathway, the FDA has approved pariglasgene brecaparvovec for glycogen storage disease type Ia.
EuropeResearch and clinical trials
A total of 58 patients from 34 centers in seven European countries were followed.
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:35
No separate ICD-11 code; WHO classifies this disease under: 5C50.E0
Codes checked against WHO ICD-11 and Orphanet on October 7, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.